D. Boral Capital Reaffirms Buy Rating for Cytosorbents (NASDAQ:CTSO)

Key Points

• D. Boral Capital has reiterated a buy rating for Cytosorbents (NASDAQ:CTSO) with a target price of $10.00.
• Cytosorbents has reported earnings exceeding analyst expectations, with a quarterly EPS of ($0.05) against a consensus estimate of ($0.07).
• Institutional investors own 32.87% of Cytosorbents' stock, with Renaissance Technologies and Goldman Sachs significantly increasing their holdings recently.

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $10.00 target price on the medical research company's stock.

CTSO has been the topic of a number of other research reports. Wall Street Zen began coverage on shares of Cytosorbents in a report on Wednesday, May 21st. They set a "hold" rating on the stock. HC Wainwright reaffirmed a "neutral" rating and set a $1.00 target price on shares of Cytosorbents in a report on Thursday, May 15th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Cytosorbents currently has an average rating of "Moderate Buy" and an average target price of $5.50.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.08 on Wednesday. The stock has a market capitalization of $67.78 million, a P/E ratio of -6.35 and a beta of 1.19. The company has a current ratio of 2.34, a quick ratio of 1.96 and a debt-to-equity ratio of 1.24. The firm's 50 day moving average is $1.07 and its 200 day moving average is $1.03. Cytosorbents has a 12 month low of $0.7101 and a 12 month high of $1.61.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The company had revenue of $9.62 million for the quarter, compared to analysts' expectations of $9.79 million. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. On average, sell-side analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its holdings in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after purchasing an additional 8,400 shares during the last quarter. Avenir Corp grew its holdings in shares of Cytosorbents by 0.3% during the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company's stock valued at $6,475,000 after purchasing an additional 13,619 shares during the last quarter. Northern Trust Corp boosted its position in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after buying an additional 16,701 shares during the period. Millennium Management LLC purchased a new stake in Cytosorbents during the 4th quarter valued at $30,000. Finally, Goldman Sachs Group Inc. boosted its position in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock valued at $63,000 after buying an additional 37,519 shares during the period. Institutional investors own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.